Lynparza (olaparib) vs Piqray (alpelisib)
Lynparza (olaparib) vs Piqray (alpelisib)
Lynparza (olaparib) is a PARP inhibitor used primarily to treat certain types of cancers, including ovarian, breast, pancreatic, and prostate cancers that have specific genetic mutations, such as BRCA mutations. Piqray (alpelisib), on the other hand, is a PI3K inhibitor indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. When deciding between Lynparza and Piqray, it is crucial to consider the specific type of cancer, the presence of genetic mutations such as BRCA or PIK3CA, and the previous treatments used, as these factors will determine the appropriateness and potential effectiveness of each medication.
Difference between Lynparza and Piqray
| Metric | Lynparza (olaparib) | Piqray (alpelisib) |
|---|---|---|
| Generic name | Olaparib | Alpelisib |
| Indications | BRCA-mutated advanced ovarian cancer, metastatic breast cancer, pancreatic cancer, prostate cancer | HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer |
| Mechanism of action | Poly (ADP-ribose) polymerase (PARP) inhibitor | Phosphatidylinositol-3-kinase (PI3K) inhibitor |
| Brand names | Lynparza | Piqray |
| Administrative route | Oral | Oral |
| Side effects | Anemia, nausea, fatigue, vomiting, respiratory infections, blood clots | Hyperglycemia, rash, diarrhea, decreased appetite, nausea, fatigue |
| Contraindications | Hypersensitivity to olaparib, breastfeeding | Hypersensitivity to alpelisib, severe hypersensitivity to peanuts or soy |
| Drug class | PARP inhibitor | PI3K inhibitor |
| Manufacturer | AstraZeneca and Merck & Co. (MSD outside the US and Canada) | Novartis |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, also known by its generic name olaparib, is a targeted therapy known as a PARP inhibitor. It has shown efficacy in the treatment of breast cancer, particularly in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. Clinical trials have demonstrated that olaparib significantly prolongs progression-free survival compared to standard chemotherapy in patients with this specific genetic profile. The efficacy of Lynparza in breast cancer is closely associated with its ability to exploit the DNA repair weaknesses in cancer cells that harbor BRCA mutations, leading to cell death and potentially slowing the progression of the disease.
In the OlympiAD trial, a phase III study, Lynparza was compared with chemotherapy of the physician's choice in patients with BRCA-mutated, HER2-negative metastatic breast cancer. The results showed that Lynparza significantly improved progression-free survival, with a median of 7.0 months compared to 4.2 months for those receiving chemotherapy. This study was pivotal in the approval of olaparib for this indication, demonstrating its benefit as a monotherapy in a targeted patient population.
Piqray (Alpelisib) Efficacy in Breast Cancer
Piqray, with the generic name alpelisib, is a PI3K inhibitor used in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. The efficacy of Piqray in this setting is attributed to its action on the PI3K pathway, which is often overactive in cancer cells, promoting growth and survival. By inhibiting this pathway, Piqray can help to slow the progression of the disease.
The SOLAR-1 clinical trial was instrumental in demonstrating the efficacy of Piqray. In this phase III study, patients with PIK3CA-mutated, advanced or metastatic breast cancer showed a significant improvement in progression-free survival when treated with the combination of alpelisib and fulvestrant compared to fulvestrant alone. The median progression-free survival was 11.0 months in the alpelisib group versus 5.7 months in the placebo group. This marked improvement in outcomes has established Piqray as a valuable treatment option for patients with this specific type of breast cancer.
Regulatory Agency Approvals
Lynparza
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Piqray
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Lynparza or Piqray today
If Lynparza or Piqray are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us